Concert Pharmaceuticals Inc

NASDAQ:CNCE   4:00:00 PM EDT
4.82
+0.07 (+1.47%)
4:00:21 PM EDT: $4.82 0.00 (0.00%)
Earnings Announcements

Concert Pharmaceuticals Reports Q3 Loss Per Share Of $0.58

Published: 11/07/2022 12:47 GMT
Concert Pharmaceuticals Inc (CNCE) - Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results.
Concert Pharmaceuticals - Under Its Current Operating Plan, Expects Its Cash, Cash Equivalents and Investments to Fund Company Through Q2 of 2023.
Concert Pharmaceuticals Inc Qtrly Loss per Share $0.58.
Revenue is expected to be $0.11 Million
Adjusted EPS is expected to be -$0.64

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.81

More details on our Analysts Page.